SCALE 2026: Ipsen to Present Phase II Corabotase Data
Key Takeaways
- Ipsen will present Phase II LANTIC data for corabotase in glabellar lines at SCALE 2026.
- Corabotase is investigational and described as the first recombinant neuroinhibitor, or RNI.
- LANTIC is evaluating moderate to severe glabellar, forehead, and lateral canthal lines.
Ipsen announced that Phase II data from the LANTIC trial of corabotase will be presented at the SCALE 2026 Symposium on May 16, 2026, in the first aesthetic glabellar lines indication for the investigational molecule.
Corabotase is described by Ipsen as a custom-designed recombinant neuroinhibitor and the first molecule in a newly designated RNI class, recognized by the World Health Organization and US Adopted Names Council. The molecule was engineered to combine an active catalytic domain A with an affinity-enhanced binding domain B.
The Phase I/II LANTIC trial is evaluating the safety and efficacy of corabotase in adults with moderate to severe upper facial lines, including glabellar lines, forehead lines, and lateral canthal lines. According to ClinicalTrials.gov, the study is active and not recruiting, with Ipsen listed as sponsor.
Ipsen previously reported positive Phase II LANTIC data in September 2025 for glabellar lines, citing rapid onset of action and clinically sustained duration of effect. The company said the trial remains ongoing, with proof-of-concept data expected later this year for forehead lines and lateral canthal lines.
“Through advanced recombinant protein engineering and proprietary manufacturing capabilities, we have created a fully custom-designed molecule that brings an active catalytic domain A together with an affinity enhanced binding domain B,” Christelle Huguet, PhD, Executive Vice President and Head of R&D at Ipsen, said in the announcement.
Source
Ipsen press release. “Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction.” Published May 16, 2026. Accessed May 16, 2026.